S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   320.71 (-0.32%)
AAPL   164.87 (-0.29%)
MSFT   280.32 (-0.92%)
META   170.25 (+1.88%)
GOOGL   117.30 (-0.14%)
AMZN   139.41 (-0.99%)
TSLA   871.27 (+0.78%)
NVDA   177.93 (-6.30%)
NIO   20.17 (-0.25%)
BABA   90.84 (-1.86%)
AMD   100.07 (-2.19%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.18 (+1.10%)
F   15.78 (+3.14%)
DIS   109.11 (+2.33%)
AMC   23.96 (+8.03%)
PYPL   96.26 (+0.99%)
PFE   49.57 (+0.61%)
NFLX   233.49 (+2.96%)
S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   320.71 (-0.32%)
AAPL   164.87 (-0.29%)
MSFT   280.32 (-0.92%)
META   170.25 (+1.88%)
GOOGL   117.30 (-0.14%)
AMZN   139.41 (-0.99%)
TSLA   871.27 (+0.78%)
NVDA   177.93 (-6.30%)
NIO   20.17 (-0.25%)
BABA   90.84 (-1.86%)
AMD   100.07 (-2.19%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.18 (+1.10%)
F   15.78 (+3.14%)
DIS   109.11 (+2.33%)
AMC   23.96 (+8.03%)
PYPL   96.26 (+0.99%)
PFE   49.57 (+0.61%)
NFLX   233.49 (+2.96%)
S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   320.71 (-0.32%)
AAPL   164.87 (-0.29%)
MSFT   280.32 (-0.92%)
META   170.25 (+1.88%)
GOOGL   117.30 (-0.14%)
AMZN   139.41 (-0.99%)
TSLA   871.27 (+0.78%)
NVDA   177.93 (-6.30%)
NIO   20.17 (-0.25%)
BABA   90.84 (-1.86%)
AMD   100.07 (-2.19%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.18 (+1.10%)
F   15.78 (+3.14%)
DIS   109.11 (+2.33%)
AMC   23.96 (+8.03%)
PYPL   96.26 (+0.99%)
PFE   49.57 (+0.61%)
NFLX   233.49 (+2.96%)
S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   320.71 (-0.32%)
AAPL   164.87 (-0.29%)
MSFT   280.32 (-0.92%)
META   170.25 (+1.88%)
GOOGL   117.30 (-0.14%)
AMZN   139.41 (-0.99%)
TSLA   871.27 (+0.78%)
NVDA   177.93 (-6.30%)
NIO   20.17 (-0.25%)
BABA   90.84 (-1.86%)
AMD   100.07 (-2.19%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.18 (+1.10%)
F   15.78 (+3.14%)
DIS   109.11 (+2.33%)
AMC   23.96 (+8.03%)
PYPL   96.26 (+0.99%)
PFE   49.57 (+0.61%)
NFLX   233.49 (+2.96%)

ESSA Pharma - EPIX Stock Forecast, Price & News

$3.11
+0.11 (+3.67%)
(As of 08/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.95
$3.17
50-Day Range
$2.48
$5.50
52-Week Range
$2.41
$20.87
Volume
383,420 shs
Average Volume
324,527 shs
Market Capitalization
$136.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00

ESSA Pharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
575.2% Upside
$21.00 Price Target
Short Interest
Healthy
1.91% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.86mentions of ESSA Pharma in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$1.93 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.01) to ($1.18) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

207th out of 1,293 stocks

Pharmaceutical Preparations Industry

81st out of 619 stocks

EPIX stock logo

About ESSA Pharma (NASDAQ:EPIX) Stock

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Analysts Set New Price Targets

Separately, Piper Sandler reduced their price target on shares of ESSA Pharma from $50.00 to $20.00 in a report on Thursday, May 12th.

ESSA Pharma Stock Performance

EPIX Stock opened at $3.00 on Monday. The company's 50-day simple moving average is $3.64 and its 200 day simple moving average is $6.02. ESSA Pharma has a 52 week low of $2.41 and a 52 week high of $21.85.

ESSA Pharma (NASDAQ:EPIX - Get Rating) (TSE:EPI) last posted its quarterly earnings results on Tuesday, May 10th. The company reported ($0.25) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.25). As a group, analysts anticipate that ESSA Pharma will post -1.01 earnings per share for the current year.

Insiders Place Their Bets

In related news, major shareholder Growth N. V. Biotech acquired 300,000 shares of ESSA Pharma stock in a transaction dated Monday, July 18th. The stock was bought at an average price of $3.16 per share, with a total value of $948,000.00. Following the transaction, the insider now directly owns 5,879,583 shares in the company, valued at approximately $18,579,482.28. The purchase was disclosed in a filing with the SEC, which is accessible through this link. In other ESSA Pharma news, major shareholder Growth N. V. Biotech acquired 300,000 shares of the business's stock in a transaction dated Monday, July 18th. The stock was bought at an average price of $3.16 per share, with a total value of $948,000.00. Following the completion of the acquisition, the insider now owns 5,879,583 shares of the company's stock, valued at $18,579,482.28. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Growth N. V. Biotech acquired 347,204 shares of the stock in a transaction on Thursday, July 14th. The stock was bought at an average price of $2.79 per share, with a total value of $968,699.16. Following the transaction, the insider now directly owns 5,337,918 shares of the company's stock, valued at approximately $14,892,791.22. The disclosure for this purchase can be found here. In the last 90 days, insiders bought 652,091 shares of company stock worth $1,931,165. 9.90% of the stock is currently owned by insiders.

Receive EPIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ESSA Pharma and its competitors with MarketBeat's FREE daily newsletter.

EPIX Stock News Headlines

EPIX Stock Gains 11.6% on Insider Buys
ESSA Pharma Inc.(EPIX)
ESSA Pharma Inc. Common Stock (EPIX)
See More Headlines
Receive EPIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ESSA Pharma and its competitors with MarketBeat's FREE daily newsletter.

EPIX Company Calendar

Last Earnings
5/10/2022
Today
8/08/2022
Fiscal Year End
9/30/2022
Next Earnings (Estimated)
11/17/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EPIX
Employees
25
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.00
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+575.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-36,810,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.41 per share

Miscellaneous

Free Float
39,658,000
Market Cap
$136.89 million
Optionable
Not Optionable
Beta
1.59

Key Executives

  • Dr. David Ross Parkinson M.D. (Age 72)
    Pres, CEO & Director
    Comp: $829.56k
  • Mr. David S. Wood C.M.A. (Age 65)
    CPA, M.B.A., MBA, CPA, CMA, Chief Financial Officer
    Comp: $532.35k
  • Mr. Peter A. Virsik M.B.A. (Age 51)
    M.S., Exec. VP & COO
    Comp: $646.75k
  • Dr. Alessandra Cesano M.D.
    Ph.D., Chief Medical Officer
  • Chandtip Chandhasin
    Exec.
  • Erica Osbourne
    Exec.
  • Erin Rudsinski
    Exec.
  • Loleta Harris
    Exec.
  • Neil Thapar
    Exec.
  • Nkengyal Barber
    Exec.













EPIX Stock - Frequently Asked Questions

Should I buy or sell ESSA Pharma stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ESSA Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" EPIX shares.
View EPIX analyst ratings
or view top-rated stocks.

What is ESSA Pharma's stock price forecast for 2022?

1 Wall Street analysts have issued 1 year price objectives for ESSA Pharma's stock. Their EPIX stock forecasts range from $20.00 to $22.00. On average, they expect the company's share price to reach $21.00 in the next twelve months. This suggests a possible upside of 581.8% from the stock's current price.
View analysts price targets for EPIX
or view top-rated stocks among Wall Street analysts.

How has ESSA Pharma's stock performed in 2022?

ESSA Pharma's stock was trading at $14.20 at the beginning of the year. Since then, EPIX stock has decreased by 78.3% and is now trading at $3.08.
View the best growth stocks for 2022 here
.

Are investors shorting ESSA Pharma?

ESSA Pharma saw a drop in short interest in July. As of July 15th, there was short interest totaling 331,400 shares, a drop of 85.2% from the June 30th total of 2,240,000 shares. Based on an average daily trading volume, of 412,600 shares, the days-to-cover ratio is presently 0.8 days. Currently, 1.9% of the shares of the stock are short sold.
View ESSA Pharma's Short Interest
.

When is ESSA Pharma's next earnings date?

ESSA Pharma is scheduled to release its next quarterly earnings announcement on Thursday, November 17th 2022.
View our EPIX earnings forecast
.

How were ESSA Pharma's earnings last quarter?

ESSA Pharma Inc. (NASDAQ:EPIX) released its earnings results on Tuesday, May, 10th. The company reported ($0.25) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.25).

What other stocks do shareholders of ESSA Pharma own?

What is ESSA Pharma's stock symbol?

ESSA Pharma trades on the NASDAQ under the ticker symbol "EPIX."

Who are ESSA Pharma's major shareholders?

ESSA Pharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Candriam S.C.A. (1.29%). Insiders that own company stock include David Ross Parkinson, Franklin M Berger and Growth N V Biotech.
View institutional ownership trends
.

How do I buy shares of ESSA Pharma?

Shares of EPIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ESSA Pharma's stock price today?

One share of EPIX stock can currently be purchased for approximately $3.08.

How much money does ESSA Pharma make?

ESSA Pharma (NASDAQ:EPIX) has a market capitalization of $135.57 million. The company earns $-36,810,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis.

How many employees does ESSA Pharma have?

ESSA Pharma employs 25 workers across the globe.

How can I contact ESSA Pharma?

ESSA Pharma's mailing address is 999 WEST BROADWAY SUITE 720, VANCOUVER A1, V5Z 1K5. The official website for the company is www.essapharma.com. The company can be reached via phone at 778-331-0962, via email at alada@troutgroup.com, or via fax at 604-738-4080.

This page (NASDAQ:EPIX) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.